ReviewBiochemical pharmacology2010
Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics.
Review in Biochemical pharmacology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 136 citations in OpenAlex.
- Phase II Study of Sunitinib in Tumors WithJCO precision oncology · 2024Trial
- Primary melanoma of the gastrointestinal tract.World journal of gastroenterology · 2026Review
- Review
- Fabrication and functional validation of a hybrid biomimetic nanovaccine (HBNV) againstBioactive materials · 2025Article
- Acral Melanoma: A Review of Its Pathogenesis, Progression, and Management.Biomolecules · 2025Review
- Recent advancements in the diagnosis and treatment of acral melanoma.Journal of Zhejiang University. Science. B · 2024Review
- Anorectal and Genital Mucosal Melanoma: Diagnostic Challenges, Current Knowledge and Therapeutic Opportunities of Rare Melanomas.Biomedicines · 2022Review
- Acral lentiginous melanoma-Population, treatment, and survival using the NCDB from 2004 to 2015.Pigment cell & melanoma research · 2021Article
- Tissue distribution of stem cell factor in adults.Experimental and molecular pathology · 2021Article
- The relationship between the number of circulating tumor cells and the prognosis in patients with esophageal squamous cell carcinoma.Journal of gastrointestinal oncology · 2021Article
- Mucosal Melanoma: Pathological Evolution, Pathway Dependency and Targeted Therapy.Frontiers in oncology · 2021Review
- Uncommon Subtypes of Malignant Melanomas: A Review Based on Clinical and Molecular Perspectives.Cancers · 2020Review
- Mutation profile of primary subungual melanomas in Caucasians.Oncotarget · 2020Article
- Contemporary Multidisciplinary Management of Sinonasal Mucosal Melanoma.OncoTargets and therapy · 2020Review
- Primary malignant melanoma of esophagus: clinicopathologic characterization of 20 cases including molecular genetic profiling of 15 tumors.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2019Article
- Recurrent hotspot SF3B1 mutations at codon 625 in vulvovaginal mucosal melanoma identified in a study of 27 Australian mucosal melanomas.Oncotarget · 2019Article
- Exploring major signaling cascades in melanomagenesis: a rationale route for targetted skin cancer therapy.Bioscience reports · 2018Review
- Genetics of metastasis: melanoma and other cancers.Clinical & experimental metastasis · 2018Review
- Diagnosis and Management of Acral Lentiginous Melanoma.Current treatment options in oncology · 2018Review
- Targeting the HGF/MET Axis Counters Primary Resistance to KIT Inhibition inJCO precision oncology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
Abstract
Despite multiple clinical trials utilizing a spectrum of therapeutic modalities, melanoma remains a disease with dismal outcomes in patients with advanced disease. However, it is now clear that melanoma is not a single entity, but can be molecularly divided into subtypes that generally correspond to the anatomical location of the primary melanoma. Melanomas from acral lentiginous, mucosal, and chronic sun-damaged sites frequently harbor activating mutations and/or increased copy number in the KIT tyrosine kinase receptor gene, which are very rare in the more common cutaneous tumors. Multiple case reports and early observations from clinical trials suggest that targeting mutant KIT with tyrosine kinase inhibitors is efficacious in KIT mutant melanoma. This review recounts what is known about the role of KIT in melanocyte maturation, our current understanding of KIT genetic aberrations in melanoma, and how this knowledge is being translated into clinical oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.